Pharmaceutical Business Review
Return to: PBR Home | News

Hikma secures right to distribute Perrigo's products in MENA markets

Published 10 July 2018

Hikma Pharmaceuticals has signed a licensing and distribution agreement with Omega Pharma Trading, an affiliate of Perrigo, a provider of over-the-counter healthcare solutions in Europe.

Under the terms of the agreement, Hikma has the exclusive right to license and distribute more than 30 consumer healthcare products, including Davitamon, Prevalin, XLS Medical, Dermalex and Paranix, in all its MENA markets, with the exception of current agreements in place.

Hikma aims to work with Perrigo’s existing partners in the MENA region to broaden sales and marketing coverage.

In addition, Hikma has the right of first refusal to the full range of Perrigo’s OTC medicines in the region.

The partnership provides a significant opportunity for Hikma to collaborate with Perrigo in MENA, building on the strengths of each company.

The agreement will leverage Hikma’s substantial local presence with operations in 17 markets and an established sales and marketing team, experienced in building brands, with particular expertise in the consumer health business.

Hikma executive vice chairman and MENA and emerging markets CEO Mazen Darwazah said: “We are very pleased to be entering a partnership with Perrigo. This agreement will expand our consumer healthcare portfolio, enabling us to meet growing demand across the region.”

Perrigo executive vice president and consumer healthcare international president Svend Andersen said: “These OTC medicines are important in meeting the healthcare needs of patients and consumers. We are pleased to partner with Hikma to leverage their strong presence in MENA markets, further increasing access to these valuable consumer products.”

Source: Company Press Release